000 | 01923 a2200529 4500 | ||
---|---|---|---|
005 | 20250513234641.0 | ||
264 | 0 | _c20010524 | |
008 | 200105s 0 0 eng d | ||
022 | _a0006-4971 | ||
024 | 7 |
_a10.1182/blood.v97.8.2323 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aSeandel, M | |
245 | 0 | 0 |
_aGrowth factor-induced angiogenesis in vivo requires specific cleavage of fibrillar type I collagen. _h[electronic resource] |
260 |
_bBlood _cApr 2001 |
||
300 |
_a2323-32 p. _bdigital |
||
500 | _aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 |
_aAllantois _xblood supply |
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aCells, Cultured _xdrug effects |
650 | 0 | 4 | _aChick Embryo |
650 | 0 | 4 |
_aChorion _xblood supply |
650 | 0 | 4 |
_aCollagen _xmetabolism |
650 | 0 | 4 |
_aCollagenases _xmetabolism |
650 | 0 | 4 |
_aEndothelial Growth Factors _xpharmacology |
650 | 0 | 4 |
_aEndothelium, Vascular _xcytology |
650 | 0 | 4 |
_aExtracellular Matrix _xmetabolism |
650 | 0 | 4 |
_aFibroblast Growth Factor 2 _xpharmacology |
650 | 0 | 4 |
_aFibroblasts _xcytology |
650 | 0 | 4 |
_aHydroxamic Acids _xpharmacology |
650 | 0 | 4 |
_aLeukocytes _xcytology |
650 | 0 | 4 |
_aLymphokines _xpharmacology |
650 | 0 | 4 |
_aMetalloendopeptidases _xanalysis |
650 | 0 | 4 |
_aNeovascularization, Physiologic _xdrug effects |
650 | 0 | 4 | _aProstheses and Implants |
650 | 0 | 4 |
_aProtease Inhibitors _xpharmacology |
650 | 0 | 4 |
_aStromal Cells _xcytology |
650 | 0 | 4 | _aSurgical Mesh |
650 | 0 | 4 |
_aTissue Inhibitor of Metalloproteinase-1 _xpharmacology |
650 | 0 | 4 | _aVascular Endothelial Growth Factor A |
650 | 0 | 4 | _aVascular Endothelial Growth Factors |
700 | 1 | _aNoack-Kunnmann, K | |
700 | 1 | _aZhu, D | |
700 | 1 | _aAimes, R T | |
700 | 1 | _aQuigley, J P | |
773 | 0 |
_tBlood _gvol. 97 _gno. 8 _gp. 2323-32 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1182/blood.v97.8.2323 _zAvailable from publisher's website |
999 |
_c11225867 _d11225867 |